{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:21:58Z","timestamp":1793103718588,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":37,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.vaccine.2024.126629","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T20:14:46Z","timestamp":1734552886000},"page":"126629","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Risk of adverse events after Omicron XBB-adapted BNT162b2 COVID-19 vaccination in the United States"],"prefix":"10.1016","volume":"45","author":[{"given":"Jenny W.","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura E.","family":"Dodge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Mather","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Goebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Charpentier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Nespithal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kofi","family":"Asomaning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence T.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.126629_bb0005","article-title":"FDA takes action on updated mRNA COVID-19 vaccines to better protect against currently circulating variants","author":"Office of the Commissioner","year":"2023","journal-title":"FDA"},{"key":"10.1016\/j.vaccine.2024.126629_bb0030","series-title":"COMIRNATY Highlights of Prescribing Information","author":"Pfizer-BioNTech","year":"2023"},{"key":"10.1016\/j.vaccine.2024.126629_bb0035","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","article-title":"Safety of the BNT162b2 mRNA Covid-19 vaccine in a Nationwide setting","volume":"385","author":"Noam","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.126629_bb0040","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1001\/jamapediatrics.2023.1440","article-title":"Safety of the BNT162b2 COVID-19 vaccine in children aged 5 to 17 years","volume":"177","author":"Hu","year":"2023","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.vaccine.2024.126629_bb0045","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1001\/jamapediatrics.2022.0001","article-title":"Association of BNT162b2 COVID-19 vaccination during pregnancy with neonatal and early infant outcomes","volume":"176","author":"Goldshtein","year":"2022","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.vaccine.2024.126629_bb0050","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jama.2021.15072","article-title":"Surveillance for adverse events after COVID-19 mRNA vaccination","volume":"326","author":"Klein","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2024.126629_bb0055","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1016\/j.vaccine.2022.07.007","article-title":"Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination","volume":"40","author":"Goddard","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126629_bb0060","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2022-057313","article-title":"Safety of COVID-19 vaccination in United States children ages 5 to 11 years","volume":"150","author":"Hause","year":"2022","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2024.126629_bb0065","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3390\/vaccines12020118","article-title":"Safety and immunogenicity of the monovalent omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine in individuals \u226512 years old: a phase 2\/3 trial","volume":"12","author":"Gayed","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2024.126629_bb0070","article-title":"Center for Biologics Evaluation and Research. Updated COVID-19 vaccines for use in the United States beginning in fall 2024","year":"2024","journal-title":"FDA"},{"key":"10.1016\/j.vaccine.2024.126629_bb0075","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2024.1036","article-title":"Adverse events after XBB.1.5-containing COVID-19 mRNA vaccines","author":"Andersson","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2024.126629_bb0080","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/pds.3217","article-title":"Vaccine discontinuation and switching following regulatory interventions in response to rotavirus vaccine contamination with porcine circovirus DNA fragments","volume":"21","author":"Dore","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2024.126629_bb0085","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/INF.0b013e3182421390","article-title":"Postmarketing evaluation of the short-term safety of the pentavalent rotavirus vaccine","volume":"31","author":"Loughlin","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2024.126629_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.02.065","article-title":"Overview of U.S. COVID-19 vaccine safety surveillance systems","author":"Gee","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126629_bb0095","series-title":"Vaccines and related biological products advisory committee June 10, 2021 meeting presentation: FDA updates of COVID-19 vaccine safety activities","author":"Anderson","year":"2021"},{"key":"10.1016\/j.vaccine.2024.126629_bb0100","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.8192","article-title":"Safety of ancestral monovalent BNT162b2, mRNA-1273, and NVX-CoV2373 COVID-19 vaccines in US children aged 6 months to 17 years","volume":"7","author":"Hu","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.vaccine.2024.126629_bb0105","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.vaccine.2022.11.003","article-title":"Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019-2020","volume":"41","author":"Moll","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126629_bb0110","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/aje\/kwu322","article-title":"A vaccine study design selection framework for the postlicensure rapid immunization safety monitoring program","volume":"181","author":"Baker","year":"2015","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2024.126629_bb0115","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/pds.5227","article-title":"Control yourself: ISPE-endorsed guidance in the application of self-controlled study designs in pharmacoepidemiology","volume":"30","author":"Cadarette","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2024.126629_bb0120","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.42240","article-title":"Assessment of herpes zoster risk among recipients of COVID-19 vaccine","volume":"5","author":"Akpandak","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.vaccine.2024.126629_bb0125","article-title":"Center for Biologics Evaluation and Research (CBER) biologics effectiveness and safety (BEST) system COVID-19 vaccine safety surveillance: active monitoring master protocol","author":"CBER","year":"2021","journal-title":"US Food Drug Adm"},{"key":"10.1016\/j.vaccine.2024.126629_bb0130","article-title":"Center for Biologics Evaluation and Research (CBER) biologics effectiveness and safety (BEST) initiative: safety assessment of 3rd dose\/booster of COVID-19 mRNA vaccines: master protocol","author":"CBER","year":"2022","journal-title":"US Food and Drug Adm"},{"key":"10.1016\/j.vaccine.2024.126629_bb0135","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1093\/infdis\/jiad306","article-title":"Stroke following coronavirus disease 2019 vaccination: evidence based on different designs of real-world studies","volume":"228","author":"Liu","year":"2023","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.126629_bb0140","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1080\/21645515.2021.1901544","article-title":"Acute disseminated encephalomyelitis and routine childhood vaccinations - a self-controlled case series","volume":"17","author":"Martin","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2024.126629_bb0145","doi-asserted-by":"crossref","first-page":"5975","DOI":"10.1016\/j.vaccine.2013.10.031","article-title":"Evaluating the safety of influenza vaccine using a claims-based health system","volume":"31","author":"McCarthy","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126629_bb0150","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.jaad.2021.07.054","article-title":"COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease: review of available evidence","volume":"85","author":"Wack","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.vaccine.2024.126629_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanepe.2023.100681","article-title":"Thrombocytopenic, thromboembolic and haemorrhagic events following second dose with BNT162b2 and ChAdOx1: self-controlled case series analysis of the English national sentinel cohort","volume":"32","author":"Joy","year":"2023","journal-title":"Lancet Regional Health - Europe"},{"key":"10.1016\/j.vaccine.2024.126629_bb0165","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/pds.4210","article-title":"Effects of expanding the look-back period to all available data in the assessment of covariates","volume":"26","author":"Nakasian","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2024.126629_bb0170","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1097\/EDE.0000000000000904","article-title":"Analysis of observational self-matched data to examine acute triggers of outcome events with abrupt onset","volume":"29","author":"Mostofsky","year":"2018","journal-title":"Epidemiology"},{"key":"10.1016\/j.vaccine.2024.126629_bb0175","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1016\/j.vaccine.2024.01.100","article-title":"COVID-19 vaccines and adverse events of special interest: a multinational global vaccine data network (GVDN) cohort study of 99 million vaccinated individuals","volume":"42","author":"Faksova","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126629_bb0180","article-title":"Evaluation of Febrile Seizure Risk Following Ancestral Monovalent COVID-19 mRNA Vaccination Among U.S. Children Aged 2\u20135 Years","author":"Forshee","year":"2024","journal-title":"medRxiv"},{"key":"10.1016\/j.vaccine.2024.126629_bb0185","first-page":"75","article-title":"Idiopathic inflammatory myopathies linked to vaccination against SARS-CoV-2: a systematic review","author":"Camargo-Coronel","year":"2023","journal-title":"Reumatismo"},{"key":"10.1016\/j.vaccine.2024.126629_bb0190","article-title":"Center for Biologics Evaluation and Research. CDC and FDA identify preliminary COVID-19 vaccine safety signal for persons aged 65 years and older","year":"2023","journal-title":"FDA"},{"key":"10.1016\/j.vaccine.2024.126629_bb0195","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1001\/jama.2024.1059","article-title":"Stroke risk after COVID-19 bivalent vaccination among US older adults","volume":"331","author":"Lu","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2024.126629_bb0200","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/S1473-3099(23)00207-4","article-title":"Safety of monovalent and bivalent BNT162b2 mRNA COVID-19 vaccine boosters in at-risk populations in Israel: a large-scale, retrospective, self-controlled case series study","volume":"23","author":"Yamin","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2024.126629_bb0205","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41541-023-00777-w","article-title":"Ischemic stroke after COVID-19 bivalent vaccine administration in patients aged 65 years and older in the United States","volume":"8","author":"Gorenflo","year":"2023","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2024.126629_bb0210","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMc2302134","article-title":"Stroke, Myocardial Infarction, and Pulmonary Embolism after Bivalent Booster","author":"Jabagi","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.126629_bb0215","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1080\/14760584.2023.2232451","article-title":"Risk of herpes zoster following mRNA COVID-19 vaccine administration","volume":"22","author":"Florea","year":"2023","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2024.126629_bb0220","article-title":"Herpes zoster related hospitalization after inactivated (CoronaVac) and mRNA (BNT162b2) SARS-CoV-2 vaccination: a self-controlled case series and nested case-control study","volume":"21","author":"Wan","year":"2022","journal-title":"Lancet Reg Health West Pac"},{"key":"10.1016\/j.vaccine.2024.126629_bb0225","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.cmi.2021.09.018","article-title":"Real-world safety data for the Pfizer BNT162b2 SARS-CoV-2 vaccine: historical cohort study","volume":"28","author":"Shasha","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2024.126629_bb0230","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/jamainternmed.2022.2109","article-title":"Comparative safety of BNT162b2 and mRNA-1273 vaccines in a Nationwide cohort of US veterans","volume":"182","author":"Dickerman","year":"2022","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.vaccine.2024.126629_bb0235","author":"CDC"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24013112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24013112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T15:13:00Z","timestamp":1739200380000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24013112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":42,"alternative-id":["S0264410X24013112"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126629","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of adverse events after Omicron XBB-adapted BNT162b2 COVID-19 vaccination in the United States","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126629","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"126629"}}